ReviewAmerican heart journal plus : cardiology research and practice2025
Phase-dependent iron dysmetabolism in myocardial ischemia-reperfusion injury: From mechanisms to therapies.
Review in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury (MIRI) remains a critical clinical challenge, often worsening myocardial damage after reperfusion therapy for acute myocardial infarction (AMI). Phase-dependent dysregulation of iron homeostasis is critically involved in the pathogenesis of MIRI. Ischemia leads to depletion of the labile iron pool (LIP) and iron accumulation in cardiomyocytes, whereas reperfusion leads to iron overload and oxidative stress. These changes destroy cellular homeostasis, triggering ferroptosis and other programmed cell death pathways. Potential therapeutic targets have been identified through molecular mechanisms regulating ferritinophagy, hepcidin modulation, and transferrin receptor 1-mediated iron transport. This review summarizes research progress in these phase-specific changes in iron metabolism during myocardial ischemia and reperfusion, emphasizing their roles in oxidative stress and cell damage. Potential therapeutic strategies integrate the correction of dysregulated homeostasis into clinical trials using drugs that target AMI and MIRI, offering perspectives for the development of novel treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.